Zhongshan School of Medicine and the Seventh Affiliated Hospital, Sun Yat-Sen University, Guangdong 510080, China; Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangdong 510080, China; Key Laboratory for Stem Cells and Tissue Engineering (Sun Yat-Sen University), Ministry of Education, Guangdong 510080, China.
Zhongshan School of Medicine and the Seventh Affiliated Hospital, Sun Yat-Sen University, Guangdong 510080, China; Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangdong 510080, China; Key Laboratory for Stem Cells and Tissue Engineering (Sun Yat-Sen University), Ministry of Education, Guangdong 510080, China.
J Mol Cell Cardiol. 2023 Aug;181:79-88. doi: 10.1016/j.yjmcc.2023.06.002. Epub 2023 Jun 17.
Heart disease continues to be the leading cause of mortality worldwide, primarily attributed to the restricted regenerative potential of the adult human heart following injury. In contrast to their adult counterparts, many neonatal mammals can spontaneously regenerate their myocardium in the first few days of life via extensive proliferation of the pre-existing cardiomyocytes. Reasons for the decline in regenerative capacity during postnatal development, and how to control it, remain largely unexplored. Accumulated evidence suggests that the preservation of regenerative potential depends on a conducive metabolic state in the embryonic and neonatal heart. Along with the postnatal increase in oxygenation and workload, the mammalian heart undergoes a metabolic transition, shifting its primary metabolic substrate from glucose to fatty acids shortly after birth for energy advantage. This metabolic switch causes cardiomyocyte cell-cycle arrest, which is widely regarded as a key mechanism for the loss of regenerative capacity. Beyond energy provision, emerging studies have suggested a link between this intracellular metabolism dynamics and postnatal epigenetic remodeling of the mammalian heart that reshapes the expression of many genes important for cardiomyocyte proliferation and cardiac regeneration, since many epigenetic enzymes utilize kinds of metabolites as obligate cofactors or substrates. This review summarizes the current state of knowledge of metabolism and metabolite-mediated epigenetic modifications in cardiomyocyte proliferation, with a particular focus on highlighting the potential therapeutic targets that hold promise to treat human heart failure via metabolic and epigenetic regulations.
心脏病仍然是全球范围内导致死亡的主要原因,主要归因于成人心脏在受伤后再生能力有限。与成人相比,许多新生哺乳动物在生命的最初几天可以通过预先存在的心肌细胞的广泛增殖自发地再生心肌。导致出生后再生能力下降的原因以及如何控制这种下降,在很大程度上仍未得到探索。越来越多的证据表明,再生潜力的保留取决于胚胎和新生儿心脏中有利的代谢状态。随着出生后氧气和工作量的增加,哺乳动物心脏经历代谢转变,其主要代谢底物从葡萄糖转变为脂肪酸,以获得能量优势。这种代谢转换导致心肌细胞细胞周期停滞,这被广泛认为是丧失再生能力的关键机制。除了提供能量之外,新兴的研究还表明,这种细胞内代谢动态与哺乳动物心脏的出生后表观遗传重塑之间存在联系,这种重塑重塑了许多对心肌细胞增殖和心脏再生很重要的基因的表达,因为许多表观遗传酶利用各种代谢物作为必需的辅助因子或底物。本综述总结了代谢和代谢物介导的表观遗传修饰在心肌细胞增殖中的最新知识状况,特别强调了通过代谢和表观遗传调控治疗人类心力衰竭的有希望的治疗靶点。